List of Tables
Table 1. Global Nintedanib Generics Market Value by Type (US$ Million), 2025 vs 2032
Table 2. Global Nintedanib Generics Market Value by Application (US$ Million), 2025 vs 2032
Table 3. Global Nintedanib Generics Market Competitive Situation by Manufacturers in 2025
Table 4. Global Nintedanib Generics Sales (K Units) of Key Manufacturers (2021–2026)
Table 5. Global Nintedanib Generics Sales Market Share by Manufacturers (2021–2026)
Table 6. Global Nintedanib Generics Revenue (US$ Million) by Manufacturers (2021–2026)
Table 7. Global Nintedanib Generics Revenue Share by Manufacturers (2021–2026)
Table 8. Global Market Nintedanib Generics Average Price (US$/Unit) of Key Manufacturers (2021–2026)
Table 9. Global Key Players of Nintedanib Generics, Industry Ranking, 2023 vs 2024 vs 2025
Table 10. Global Key Manufacturers of Nintedanib Generics, Manufacturing Sites and Headquarters
Table 11. Global Key Manufacturers of Nintedanib Generics, Product Types and Applications
Table 12. Global Key Manufacturers of Nintedanib Generics, Date of Entry into the Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Nintedanib Generics Companies by Tier (Tier 1, Tier 2, Tier 3), based on Nintedanib Generics Revenue, 2025
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Nintedanib Generics Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 17. Global Nintedanib Generics Sales by Region (K Units), 2021–2026
Table 18. Global Nintedanib Generics Sales Market Share by Region (2021–2026)
Table 19. Global Nintedanib Generics Sales by Region (K Units), 2027–2032
Table 20. Global Nintedanib Generics Sales Market Share by Region (2027–2032)
Table 21. Global Nintedanib Generics Revenue by Region (US$ Million), 2021–2026
Table 22. Global Nintedanib Generics Revenue Market Share by Region (2021–2026)
Table 23. Global Nintedanib Generics Revenue by Region (US$ Million), 2027–2032
Table 24. Global Nintedanib Generics Revenue Market Share by Region (2027–2032)
Table 25. North America Nintedanib Generics Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 26. North America Nintedanib Generics Sales by Country (K Units), 2021–2026
Table 27. North America Nintedanib Generics Sales by Country (K Units), 2027–2032
Table 28. North America Nintedanib Generics Revenue by Country (US$ Million), 2021–2026
Table 29. North America Nintedanib Generics Revenue by Country (US$ Million), 2027–2032
Table 30. Europe Nintedanib Generics Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 31. Europe Nintedanib Generics Sales by Country (K Units), 2021–2026
Table 32. Europe Nintedanib Generics Sales by Country (K Units), 2027–2032
Table 33. Europe Nintedanib Generics Revenue by Country (US$ Million), 2021–2026
Table 34. Europe Nintedanib Generics Revenue by Country (US$ Million), 2027–2032
Table 35. Asia Pacific Nintedanib Generics Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 36. Asia Pacific Nintedanib Generics Sales by Region (K Units), 2021–2026
Table 37. Asia Pacific Nintedanib Generics Sales by Region (K Units), 2027–2032
Table 38. Asia Pacific Nintedanib Generics Revenue by Region (US$ Million), 2021–2026
Table 39. Asia Pacific Nintedanib Generics Revenue by Region (US$ Million), 2027–2032
Table 40. Latin America Nintedanib Generics Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 41. Latin America Nintedanib Generics Sales by Country (K Units), 2021–2026
Table 42. Latin America Nintedanib Generics Sales by Country (K Units), 2027–2032
Table 43. Latin America Nintedanib Generics Revenue by Country (US$ Million), 2021–2026
Table 44. Latin America Nintedanib Generics Revenue by Country (US$ Million), 2027–2032
Table 45. Middle East and Africa Nintedanib Generics Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 46. Middle East and Africa Nintedanib Generics Sales by Country (K Units), 2021–2026
Table 47. Middle East and Africa Nintedanib Generics Sales by Country (K Units), 2027–2032
Table 48. Middle East and Africa Nintedanib Generics Revenue by Country (US$ Million), 2021–2026
Table 49. Middle East and Africa Nintedanib Generics Revenue by Country (US$ Million), 2027–2032
Table 50. Global Nintedanib Generics Sales (K Units) by Type (2021–2026)
Table 51. Global Nintedanib Generics Sales (K Units) by Type (2027–2032)
Table 52. Global Nintedanib Generics Sales Market Share by Type (2021–2026)
Table 53. Global Nintedanib Generics Sales Market Share by Type (2027–2032)
Table 54. Global Nintedanib Generics Revenue (US$ Million) by Type (2021–2026)
Table 55. Global Nintedanib Generics Revenue (US$ Million) by Type (2027–2032)
Table 56. Global Nintedanib Generics Revenue Market Share by Type (2021–2026)
Table 57. Global Nintedanib Generics Revenue Market Share by Type (2027–2032)
Table 58. Global Nintedanib Generics Price (US$/Unit) by Type (2021–2026)
Table 59. Global Nintedanib Generics Price (US$/Unit) by Type (2027–2032)
Table 60. Global Nintedanib Generics Sales (K Units) by Application (2021–2026)
Table 61. Global Nintedanib Generics Sales (K Units) by Application (2027–2032)
Table 62. Global Nintedanib Generics Sales Market Share by Application (2021–2026)
Table 63. Global Nintedanib Generics Sales Market Share by Application (2027–2032)
Table 64. Global Nintedanib Generics Revenue (US$ Million) by Application (2021–2026)
Table 65. Global Nintedanib Generics Revenue (US$ Million) by Application (2027–2032)
Table 66. Global Nintedanib Generics Revenue Market Share by Application (2021–2026)
Table 67. Global Nintedanib Generics Revenue Market Share by Application (2027–2032)
Table 68. Global Nintedanib Generics Price (US$/Unit) by Application (2021–2026)
Table 69. Global Nintedanib Generics Price (US$/Unit) by Application (2027–2032)
Table 70. Cipla Company Information
Table 71. Cipla Description and Business Overview
Table 72. Cipla Nintedanib Generics Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 73. Cipla Nintedanib Generics Product
Table 74. Cipla Recent Developments/Updates
Table 75. Beacon Pharma Company Information
Table 76. Beacon Pharma Description and Business Overview
Table 77. Beacon Pharma Nintedanib Generics Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 78. Beacon Pharma Nintedanib Generics Product
Table 79. Beacon Pharma Recent Developments/Updates
Table 80. Eskayef Pharmaceuticals Company Information
Table 81. Eskayef Pharmaceuticals Description and Business Overview
Table 82. Eskayef Pharmaceuticals Nintedanib Generics Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 83. Eskayef Pharmaceuticals Nintedanib Generics Product
Table 84. Eskayef Pharmaceuticals Recent Developments/Updates
Table 85. Glenmark Company Information
Table 86. Glenmark Description and Business Overview
Table 87. Glenmark Nintedanib Generics Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 88. Glenmark Nintedanib Generics Product
Table 89. Glenmark Recent Developments/Updates
Table 90. CSPC Pharmaceutical Group Company Information
Table 91. CSPC Pharmaceutical Group Description and Business Overview
Table 92. CSPC Pharmaceutical Group Nintedanib Generics Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 93. CSPC Pharmaceutical Group Nintedanib Generics Product
Table 94. CSPC Pharmaceutical Group Recent Developments/Updates
Table 95. Qilu Pharmaceutical Company Information
Table 96. Qilu Pharmaceutical Description and Business Overview
Table 97. Qilu Pharmaceutical Nintedanib Generics Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 98. Qilu Pharmaceutical Nintedanib Generics Product
Table 99. Qilu Pharmaceutical Recent Developments/Updates
Table 100. PuraCap Company Information
Table 101. PuraCap Description and Business Overview
Table 102. PuraCap Nintedanib Generics Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 103. PuraCap Nintedanib Generics Product
Table 104. PuraCap Recent Developments/Updates
Table 105. Jiangsu Wangao Pharmaceutical Company Information
Table 106. Jiangsu Wangao Pharmaceutical Description and Business Overview
Table 107. Jiangsu Wangao Pharmaceutical Nintedanib Generics Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 108. Jiangsu Wangao Pharmaceutical Nintedanib Generics Product
Table 109. Jiangsu Wangao Pharmaceutical Recent Developments/Updates
Table 110. Kelun Pharmaceutical Company Information
Table 111. Kelun Pharmaceutical Description and Business Overview
Table 112. Kelun Pharmaceutical Nintedanib Generics Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 113. Kelun Pharmaceutical Nintedanib Generics Product
Table 114. Kelun Pharmaceutical Recent Developments/Updates
Table 115. Key Raw Materials Lists
Table 116. Raw Materials Key Suppliers Lists
Table 117. Nintedanib Generics Distributors List
Table 118. Nintedanib Generics Customers List
Table 119. Nintedanib Generics Market Trends
Table 120. Nintedanib Generics Market Drivers
Table 121. Nintedanib Generics Market Challenges
Table 122. Nintedanib Generics Market Restraints
Table 123. Research Programs/Design for This Report
Table 124. Key Data Information from Secondary Sources
Table 125. Key Data Information from Primary Sources
Table 126. Authors List of This Report
List of Figures
Figure 1. Product Picture of Nintedanib Generics
Figure 2. Global Nintedanib Generics Market Value by Type (US$ Million), 2021–2032
Figure 3. Global Nintedanib Generics Market Share by Type: 2025 & 2032
Figure 4. 100mg per Unit Product Picture
Figure 5. 150mg per Unit Product Picture
Figure 6. Global Nintedanib Generics Market Value by Application (US$ Million), 2021–2032
Figure 7. Global Nintedanib Generics Market Share by Application: 2025 & 2032
Figure 8. Non-small Cell Lung Cancer
Figure 9. Idiopathic Pulmonary Fibrosis
Figure 10. Other
Figure 11. Global Nintedanib Generics Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 12. Global Nintedanib Generics Market Size (US$ Million), 2021–2032
Figure 13. Global Nintedanib Generics Sales (K Units), 2021–2032
Figure 14. Global Nintedanib Generics Average Price (US$/Unit), 2021–2032
Figure 15. Nintedanib Generics Report Years Considered
Figure 16. Nintedanib Generics Sales Share by Manufacturers in 2025
Figure 17. Global Nintedanib Generics Revenue Share by Manufacturers in 2025
Figure 18. Top 5 and Top 10 Global Nintedanib Generics Players: Market Share by Revenue in Nintedanib Generics in 2025
Figure 19. Nintedanib Generics Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
Figure 20. Global Nintedanib Generics Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Figure 21. North America Nintedanib Generics Sales Market Share by Country (2021–2032)
Figure 22. North America Nintedanib Generics Revenue Market Share by Country (2021–2032)
Figure 23. United States Nintedanib Generics Revenue Growth Rate (US$ Million), 2021–2032
Figure 24. Canada Nintedanib Generics Revenue Growth Rate (US$ Million), 2021–2032
Figure 25. Europe Nintedanib Generics Sales Market Share by Country (2021–2032)
Figure 26. Europe Nintedanib Generics Revenue Market Share by Country (2021–2032)
Figure 27. Germany Nintedanib Generics Revenue Growth Rate (US$ Million), 2021–2032
Figure 28. France Nintedanib Generics Revenue Growth Rate (US$ Million), 2021–2032
Figure 29. U.K. Nintedanib Generics Revenue Growth Rate (US$ Million), 2021–2032
Figure 30. Italy Nintedanib Generics Revenue Growth Rate (US$ Million), 2021–2032
Figure 31. Russia Nintedanib Generics Revenue Growth Rate (US$ Million), 2021–2032
Figure 32. Asia Pacific Nintedanib Generics Sales Market Share by Region (2021–2032)
Figure 33. Asia Pacific Nintedanib Generics Revenue Market Share by Region (2021–2032)
Figure 34. China Nintedanib Generics Revenue Growth Rate (US$ Million), 2021–2032
Figure 35. Japan Nintedanib Generics Revenue Growth Rate (US$ Million), 2021–2032
Figure 36. South Korea Nintedanib Generics Revenue Growth Rate (US$ Million), 2021–2032
Figure 37. India Nintedanib Generics Revenue Growth Rate (US$ Million), 2021–2032
Figure 38. Australia Nintedanib Generics Revenue Growth Rate (US$ Million), 2021–2032
Figure 39. China Taiwan Nintedanib Generics Revenue Growth Rate (US$ Million), 2021–2032
Figure 40. Southeast Asia Nintedanib Generics Revenue Growth Rate (US$ Million), 2021–2032
Figure 41. Latin America Nintedanib Generics Sales Market Share by Country (2021–2032)
Figure 42. Latin America Nintedanib Generics Revenue Market Share by Country (2021–2032)
Figure 43. Mexico Nintedanib Generics Revenue Growth Rate (US$ Million), 2021–2032
Figure 44. Brazil Nintedanib Generics Revenue Growth Rate (US$ Million), 2021–2032
Figure 45. Argentina Nintedanib Generics Revenue Growth Rate (US$ Million), 2021–2032
Figure 46. Colombia Nintedanib Generics Revenue Growth Rate (US$ Million), 2021–2032
Figure 47. Middle East and Africa Nintedanib Generics Sales Market Share by Country (2021–2032)
Figure 48. Middle East and Africa Nintedanib Generics Revenue Market Share by Country (2021–2032)
Figure 49. Turkey Nintedanib Generics Revenue Growth Rate (US$ Million), 2021–2032
Figure 50. Saudi Arabia Nintedanib Generics Revenue Growth Rate (US$ Million), 2021–2032
Figure 51. UAE Nintedanib Generics Revenue Growth Rate (US$ Million), 2021–2032
Figure 52. Global Sales Market Share of Nintedanib Generics by Type (2021–2032)
Figure 53. Global Revenue Market Share of Nintedanib Generics by Type (2021–2032)
Figure 54. Global Nintedanib Generics Price (US$/Unit) by Type (2021–2032)
Figure 55. Global Sales Market Share of Nintedanib Generics by Application (2021–2032)
Figure 56. Global Revenue Market Share of Nintedanib Generics by Application (2021–2032)
Figure 57. Global Nintedanib Generics Price (US$/Unit) by Application (2021–2032)
Figure 58. Nintedanib Generics Value Chain
Figure 59. Channels of Distribution (Direct Vs Distribution)
Figure 60. Bottom-up and Top-down Approaches for This Report
Figure 61. Data Triangulation
Figure 62. Key Executives Interviewed
